A Phase I, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Reactogenicity, and Immunogenicity of MVA-BN Yellow Fever Vaccine With and Without Montanide ISA 720 Adjuvant in 18-45 Year Old Healthy Adults
Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 04 Oct 2017
At a glance
- Drugs MVA BN YF (Primary) ; Montanide ISA-720; Smallpox vaccine; Yellow fever vaccine
- Indications Yellow fever
- Focus Adverse reactions
- 10 Aug 2017 Planned End Date changed from 29 Dec 2017 to 17 May 2018.
- 10 Aug 2017 Planned primary completion date changed from 25 Jul 2017 to 29 Dec 2017.
- 13 Jul 2017 Planned primary completion date changed from 31 Mar 2017 to 25 Jul 2017.